

---

**FOR IMMEDIATE RELEASE**

CONTACT:  
Nick Wasmiller  
Seyferth & Associates Inc.  
1-800-435-9539  
[wasmiller@seyferthpr.com](mailto:wasmiller@seyferthpr.com)

**METABOLIC SOLUTIONS DEVELOPMENT COMPANY**  
**NAMES CHIEF EXECUTIVE OFFICER**

KALAMAZOO, MICH. (Aug. 4, 2009) – Metabolic Solutions Development Company (MSDC), a drug discovery and development firm, has named Robert A. Beardsley, Ph.D. as its chief executive officer.

“We’re excited to add a talented professional such as Robert to the Metabolic Solutions Development Company team,” said Mark Olesnavage, former acting CEO of MSDC and president of Hopen Therapeutics, the lead investor in MSDC. “Robert has sat on both sides of the table, leading a startup life science company and serving as a managing partner at a private equity partnership. We look for him to continue to build upon our value with the strategic direction that MSDC is pursuing.”

Beardsley previously served as president and chief executive officer of Kereos, Inc. in St. Louis. During Beardsley’s tenure at Kereos, the firm raised approximately \$25 million and he managed collaborations with national healthcare organizations and top academic partners. Prior to joining Kereos, Beardsley served as interim chief executive of Metaphore Pharmaceuticals, a clinical-stage, venture-backed biotech firm, and as co-founder and managing partner of Smile Investors.

“MSDC is pursuing a very exciting approach to one of the most rapidly growing diseases in the US and abroad, type 2 diabetes,” said Beardsley. “The recent Phase IIa data is compelling, and it is exciting to be joining the company when it is on the verge of something big.”

-more-

## MSDC names CEO – Page 2

“We look forward to working with Robert to advance MSDC toward our ultimate goals,” said Jerry Colca, president and chief scientific officer of MSDC. “His diverse experience base and scientific background will be great attributes when it comes to strategic planning.”

Beardsley is currently a board member of KemPharm, Inc., Galera Therapeutics and BioSeek, Inc. He earned a Ph.D. in biochemical engineering from the University of Iowa, a master’s of business administration from the University of Chicago and a bachelor’s degree in chemical engineering from the University of Iowa.

MSDC announced in May that, according to preliminary data derived from the company’s Phase IIa clinical trial, its lead compound can improve insulin sensitivity and lower blood glucose levels in humans without the side effects of current therapies when taken over a 28-day period. Additional safety and expanded efficacy data will be gathered in a 90-day, multinational Phase IIb study that is planned for first quarter 2010.

###

*Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes. This new approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain.*

*The company’s scientific strategy is built on a historical understanding of insulin-sensitizing thiazolidinediones (TZDs) and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.*